Marketing exclusivity, patent listings, and biosimilar clinical bridging study waivers are key areas of concern for biopharmaceutical industry trade associations when it comes to potential actions the US FDA might take to promote biological competition and innovation.
In comments submitted to the public docket related to FDA’s Sept. 4 public hearing, the Biotechnology Innovation Organization (BIO) and...






